Iterum Therapeutics plc (ITRM) Stock Analysis & Investment Frameworks
Iterum Therapeutics plc (ITRM) stock analysis on Invetso. Review Iterum Therapeutics plc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Iterum Therapeutics plc Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: IE
Iterum Therapeutics plc Key Financial Metrics
- Market Cap: $1.60M
- Revenue: $N/A
- ROE: 274.90%
- ROIC: -48.99%
- Dividend Yield: N/A
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland.
Iterum Therapeutics plc Investment Frameworks
Invetso analyzes Iterum Therapeutics plc (ITRM) across the following frameworks:
- Iterum Therapeutics plc 10Y Growth Potential
- Iterum Therapeutics plc Scenario Analysis
- Iterum Therapeutics plc Risks & Opportunities
- Iterum Therapeutics plc Economic Moat
- Iterum Therapeutics plc Business Model
- Iterum Therapeutics plc Management
- Iterum Therapeutics plc SWOT Analysis
- Iterum Therapeutics plc Porter's 5 Forces
- Iterum Therapeutics plc PESTLE Analysis
- Iterum Therapeutics plc ESG Analysis